Kun‐Huei Yeh

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh et al. · The Lancet · 2017 · 2.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Jin Li, Shukui Qin, Rui‐Hua Xu et al. · The Lancet Oncology · 2015 · 816 citations

Medicine, Oncology, Pharmacotherapy +10

p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27

Lyuben Tsvetkov, Kun‐Huei Yeh, Soo-Jung Lee et al. · Current Biology · 1999 · 791 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

Milind Javle, Maeve A. Lowery, Rachna T. Shroff et al. · Journal of Clinical Oncology · 2017 · 715 citations

Medicine, Oncology, Pharmacology +15